WallStSmart
KYMR

Kymera Therapeutics Inc

NASDAQ: KYMR · HEALTHCARE · BIOTECHNOLOGY

$81.51
-2.79% today

Updated 2026-04-29

Market cap
$6.65B
P/E ratio
P/S ratio
169.71x
EPS (TTM)
$-3.69
Dividend yield
52W range
$28 – $103
Volume
0.7M

Kymera Therapeutics Inc (KYMR) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$2.93M$34.03M$72.83M$46.83M$78.59M$47.07M$39.20M
Revenue growth (YoY)+1060.0%+114.0%-35.7%+67.8%-40.1%-16.7%
Cost of revenue$205000.00$825000.00$62.10M$2.40M$2.98M$189.08M$7.37M
Gross profit$-205000.00$2.11M$34.03M$72.83M$46.83M$78.59M$47.07M$39.20M
Gross margin71.9%100.0%100.0%100.0%100.0%100.0%100.0%
R&D$17.68M$37.16M$62.10M$137.02M$164.25M$189.08M$240.25M$316.60M
SG&A$3.77M$7.98M$18.23M$36.34M$43.83M$55.04M$63.53M$68.20M
Operating income$-21.45M$-42.20M$-46.30M$-100.53M$-161.26M$-165.53M$-261.63M$-349.40M
Operating margin-1438.5%-136.1%-138.0%-344.4%-210.6%-555.8%-891.3%
EBITDA$-21.25M$-40.38M$-43.72M$-97.64M$-151.66M$-143.20M$-216.24M$-303.06M
EBITDA margin-1376.1%-128.4%-134.1%-323.9%-182.2%-459.4%-773.1%
EBIT$-21.45M$-41.20M$-45.48M$-100.04M$-154.63M$-146.77M$-223.61M$-311.37M
Interest expense$16000.00$46000.00$115000.00$175000.00$176000.00$196000.00$249000.00$249000.00
Income tax$43859.00$46000.00$-1.65M$-2.22M$-2.98M$18.76M
Effective tax rate-0.2%-0.1%3.5%2.2%1.9%-14.6%0.0%0.0%
Net income$-21.47M$-41.29M$-45.59M$-100.22M$-154.81M$-146.96M$-223.86M$-311.40M
Net income growth (YoY)-92.4%-10.4%-119.8%-54.5%+5.1%-52.3%-39.1%
Profit margin-1407.4%-134.0%-137.6%-330.6%-187.0%-475.6%-794.4%